# EDGAR Filing Document

**Accession Number:** 0001932393
**File Stem:** 0001932393-23-000007
**Filing Date:** 2023-1
**Character Count:** 62002
**Document Hash:** e1944f30095c256888679cd748161d5f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001932393-23-000007.hdr.sgml**: 20230130

**ACCESSION NUMBER**: 0001932393-23-000007

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230130

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230130

**DATE AS OF CHANGE**: 20230130

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GE HealthCare Technologies Inc.
- **CENTRAL INDEX KEY:** 0001932393
- **STANDARD INDUSTRIAL CLASSIFICATION:** X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS [3844]
- **IRS NUMBER:** 882515116
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41528
- **FILM NUMBER:** 23565139

**BUSINESS ADDRESS:**
- **STREET 1:** 500 WEST MONROE STREET
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60661
- **BUSINESS PHONE:** 203-360-4369

**MAIL ADDRESS:**
- **STREET 1:** 500 WEST MONROE STREET
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60661

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GE Healthcare Holding LLC
- **DATE OF NAME CHANGE:** 20220603

?xml version="1.0" ? gehc-20230130

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

 **Washington, D.C. 20549**

**FORM 8-K** 

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) **January 30, 2023**

**<u>GE HEALTHCARE TECHNOLOGIES INC.</u>**

(Exact name of registrant as specified in its charter)

---

| | | | | |
|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;**Delaware** | &nbsp;&nbsp;**Delaware** | &nbsp;&nbsp;**Delaware** | **001-41528** | **88-2515116** |
| (State or other jurisdiction <br>of incorporation) | (State or other jurisdiction <br>of incorporation) | (State or other jurisdiction <br>of incorporation) | (Commission<br> File Number) | (IRS Employer<br>Identification No.) |
| **500 W. Monroe Street** | **Chicago,** | **IL** |  | **60661** |
| (Address of principal executive offices) | (Address of principal executive offices) | (Address of principal executive offices) |  | (Zip Code) |

---

(Registrant's telephone number, including area code) **<u>(617) 443-3400</u>**

______________________________________________

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common stock, par value $0.01 per share | GEHC | The Nasdaq Stock Market LLC |

---

---

| | |
|:---|:---|
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). | |
| Emerging growth company | ☐ |
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. | ☐ |

---

------

**Item 2.02 Results of Operations and Financial Condition.**

On January 30, 2023, GE HealthCare Technologies Inc. ("GE HealthCare") issued a press release announcing its fourth quarter and fiscal year ended December 31, 2022 financial results. A copy of this press release is furnished as Exhibit 99 to this Current Report on Form 8-K.

The information furnished pursuant to Item 2.02, including Exhibit 99, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of GE HealthCare under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;**(d) Exhibits**

---

| | |
|:---|:---|
| **<u>Exhibit</u>** | **<u>Description</u>** |
| **99** | <u>[Press release of GE HealthCare Technologies Inc., dated](a4q22earningsrelease_earni.htm)[January 30, 2023](a4q22earningsrelease_earni.htm)[.](a4q22earningsrelease_earni.htm)</u> |
| **104** | The cover page of this Current Report on Form 8-K, formatted in Inline XBRL. |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| | GE HealthCare Technologies Inc. |
| | (Registrant) |
| Date: January 30, 2023 | /s/ George A. Newcomb |
| | George A. Newcomb, Chief Accounting Officer (authorized signatory) |

---

## Ex-99

![ge-hlthcr_standardxrgbxgeh.jpg](ge-hlthcr_standardxrgbxgeh.jpg)

**Exhibit 99**

**GE HealthCare Reports Fourth Quarter and Full Year 2022 Financial Results**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *4Q Revenues up 8% year-over-year, Organic revenues\* up 13%*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *4Q Net income of $554 million versus $564 million for the prior year, Adjusted EBIT\* of $844 million versus $827 million*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *4Q EPS were $1.21 versus $1.24 in the prior year, Adjusted EPS\* were $1.31 versus $1.36*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*• Reaffirmed 2023 guidance disclosed earlier this month; introduced 2023 Adjusted EPS\* guidance*

**Chicago, IL – January 30, 2023 –** GE HealthCare (Nasdaq: GEHC), a leading global precision care innovator, today reported financial results for the fourth quarter and full year ended December 31, 2022.

GE HealthCare President and CEO Peter Arduini said, "GE HealthCare delivered strong revenue growth in the fourth quarter and full year 2022 driven by robust end market demand, improved pricing, and easing supply chain pressures. Revenue growth reflects our progress to offset delivery challenges and improve product fulfillment."

Arduini continued, "Looking ahead, we're confident that our accelerated investment in innovation, as well as standardization across platforms, will drive revenue and margin growth. We're seeing customers continue to invest along with macroeconomic tailwinds, such as increasing healthcare digitization, expanding access to care, and an aging population globally. We are well positioned to deliver on our 2023 commitments."

**Fourth quarter 2022 total financial performance** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Revenues of $4.9 billion increased 8% and 13% on an Organic basis\* year-over-year, driven by growth in Imaging, Patient Care Solutions (PCS), and Ultrasound. Acquisitions favorably impacted total revenue growth by 1% and foreign exchange negatively impacted growth by 6%. Total company book-to-bill, defined as Total orders divided by Total revenues within a given financial period, was 1.07 times for the quarter, led by strong order growth in Imaging and Ultrasound.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net income was $554 million versus $564 million for the prior year, and Adjusted EBIT\* was $844 million versus $827 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net income margin was 11.2% versus 12.3% for the prior year, and Adjusted EBIT margin\* was 17.1% versus 18.0%. Both measures were impacted by inflation, mix, planned R&D investment, and foreign exchange headwinds, partially offset by price and volume gains. Standalone Adjusted EBIT margin\* for the fourth quarter of 2022 is estimated at 16.1%, which includes the impact of standalone costs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Earnings per share (EPS) from continuing operations were $1.21, compared to $1.24 in the prior year. Adjusted EPS\* were $1.31, compared to $1.36 in the prior year. Standalone Adjusted EPS\* for the fourth quarter of 2022 were estimated at $1.06, which includes the impact of standalone costs, interest, and tax.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Cash flow from operating activities was $1.1 billion, up $1.1 billion year-over-year, and Free cash flow\* was $987 million, up $436 million year-over-year with improvement in supply chain and collections.

\* Non-GAAP financial measure.

------

**Fourth quarter 2022 segment financial performance**

***Imaging***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Revenues of $2.7 billion increased 11% and 18% on an Organic basis\* year-over-year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Strong revenue growth was driven by Molecular Imaging and Computed Tomography, Magnetic Resonance, and surgery.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Segment EBIT was $321 million versus $317 million for the prior year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Segment EBIT margin was 11.8% versus 13.0% for prior year, pressured by continued inflation, mix, and investment, partially offset by volume and price.

***Ultrasound***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Revenues of $956 million increased 6% and 7% on an Organic basis\* year-over-year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Solid revenue growth led by Radiology and Primary Care, Women's Health, Cardiovascular, as well as handheld ultrasound.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Segment EBIT was $285 million versus $278 million for the prior year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Segment EBIT margin was 29.8% versus 31.0% for prior year, impacted by inflation and investment, partially offset by price.

***Patient Care Solutions***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Revenues of $786 million increased 7% and 10% on an Organic basis\* year-over-year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Strong revenue improvement driven by impact of supply chain resiliency and price actions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Segment EBIT was $130 million versus $91 million for the prior year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Segment EBIT margin was 16.5% versus 12.4% for prior year, improved through price, volume, and lower costs, partially offset by inflation.

***Pharmaceutical Diagnostics***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Revenues of $473 million decreased 5% and increased 2% on an Organic basis\* year-over-year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Revenue was impacted by fewer procedures in China and normalization of U.S. customer inventory.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Segment EBIT of $109 million versus $139 million for the prior year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Segment EBIT margin was 23.0% versus 27.8% for prior year, impacted by inflationary pressures on production materials and lower volumes.

**Full year 2022 total financial performance** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Revenues of $18.3 billion increased 4% and 7% on an Organic basis\* year-over-year, driven by Imaging and Ultrasound. Acquisitions favorably impacted total revenue growth by 1%, and foreign exchange negatively impacted growth by 4%. Total company book-to-bill was 1.08 times for the full year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net income was $1.9 billion versus $2.2 billion for the prior year, and Adjusted EBIT\* of $2.9 billion versus $3.2 billion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net income margin was 10.4% versus 12.8% for the prior year, and Adjusted EBIT margin\* was 15.6% versus 18.0%. Both measures were affected by inflationary pressures and planned R&D investments, partially offset by volume and price. Standalone Adjusted EBIT margin\* for the full year 2022 is estimated at 14.5%, which includes the impact of standalone costs.

\* Non-GAAP financial measure.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• EPS from continuing operations were $4.18 compared to $4.91 for full year 2021. Adjusted EPS\* were $4.63, compared to $5.17 in prior year. Results continued to be impacted by inflation and planned R&D investments. Standalone Adjusted EPS\* for full year 2022 were estimated at $3.38, which includes the impact of standalone costs, interest, and tax.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Cash flow from operating activities was $2.1 billion versus $1.6 billion for the prior year, and Free cash flow\* was $1.8 billion versus $2.8 billion, impacted by supply chain pressures and lower Adjusted EBIT\*.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Cash flow conversion, defined as cash from operating activities divided by net income attributable to GE HealthCare, was 111% while Free cash flow conversion\* was 87% for 2022.

**Growth and Innovation** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Announced agreement to acquire IMACTIS to strengthen capabilities in interventional guidance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• AIR Recon DL technology recognized by *Popular Science* magazine in the 'Best of What's New' awards.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• MediView collaboration to integrate medical imaging into mixed reality solutions through the development of the OmnifyXR<sup>TM</sup> interventional suite system.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Introduced SIGNA Experience: a new platform of transformative technologies that leverages the power of AI and deep-learning in MRI scanning.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Announced $80 million investment to expand contrast media production capacity.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• GE HealthCare and Accuray collaborate to expand access, advance the practice of precision radiation therapy.

**Outlook**

Today, the Company reaffirmed its guidance for full year 2023 and introduced Adjusted EPS\* guidance as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Organic revenue growth\* in the range of 5% to 7% year-over-year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBIT margin\* in the range of 15.0% to 15.5%, reflecting an expansion of 50 to 100 basis points versus 2022 Standalone Adjusted EBIT margin\* of 14.5%.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted effective tax rate (ETR)\* in the range of 23% to 25%.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EPS\* in the range of $3.60 to $3.75. This compares to 2022 Standalone Adjusted EPS\* of $3.38.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Free cash flow conversion\* of 85% or more for the full year. The Company's cash flow outlook assumes that the legislation requiring R&D capitalization for tax purposes is repealed or deferred beyond 2023. The Free cash flow\* impact of this legislation is approximately 10 points of Free cash flow conversion\* for the year.

The Company provides its outlook on a non-GAAP basis. Refer to the Non-GAAP Financial Measures in Outlook section below for more details.

\* Non-GAAP financial measure.

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months ended December 31** | **Three Months ended December 31** | **Years ended December 31** | **Years ended December 31** |
| **Unaudited Combined Statements of Income**<br><br>***(In millions)*** | **2022** | **2021** | **2022** | **2021** |
| Sales of products | $3342 | $2956 | $12044 | $11165 |
| Sales of services | 1596 | 1633 | 6297 | 6420 |
| **Total revenues** | **4938** | **4589** | **18341** | **17585** |
| Cost of products | 2150 | 1901 | 7975 | 7196 |
| Cost of services | 856 | 826 | 3187 | 3215 |
| **Gross profit** | **1932** | **1862** | **7179** | **7174** |
| Selling, general, and administrative | 884 | 910 | 3631 | 3563 |
| Research and development | 271 | 225 | 1026 | 816 |
| **Total operating expenses** | **1155** | **1135** | **4657** | **4379** |
| **Operating income** | **777** | **727** | **2522** | **2795** |
| Interest and other financial charges – net | 59 | 6 | 77 | 40 |
| Non-operating benefit (income) costs | (1) | 1 | (5) | 3 |
| Other (income) expense – net | 1 | (35) | (62) | (123) |
| **Income from continuing operations before income taxes** | **718** | **755** | **2512** | **2875** |
| Benefit (provision) for income taxes | (151) | (179) | (563) | (600) |
| **Net income from continuing operations** | **567** | **576** | **1949** | **2275** |
| Income from discontinued operations, net of taxes | 6 |  | 18 | 18 |
| **Net income** | **573** | **576** | **1967** | **2293** |
| Net (income) attributable to noncontrolling interests | (19) | (12) | (51) | (46) |
| **Net income attributable to GE HealthCare** | $**554** | $**564** | $**1916** | $**2247** |

---

\* Non-GAAP financial measure.

------

---

| | | |
|:---|:---|:---|
| | **As of** | **As of** |
| **Unaudited Combined Statements of Financial Position**<br>***(In millions, except share and per share amounts)*** | **December 31, 2022** | **December 31, 2021** |
| Cash, cash equivalents, and restricted cash | $1445 | $556 |
| Receivables – net of allowances of $91 and $107 | 3295 | 3227 |
| Due from related parties | 17 | 32 |
| Inventories | 2155 | 1946 |
| Contract and other deferred assets | 989 | 802 |
| All other current assets | 417 | 437 |
| **Current assets** | **8318** | **7000** |
| Property, plant, and equipment – net | 2314 | 2235 |
| Goodwill | 12813 | 12892 |
| Other intangible assets – net | 1520 | 1847 |
| Deferred income taxes | 1550 | 1287 |
| All other assets | 1024 | 1047 |
| **Total assets** | $**27539** | $**26308** |
| Short-term borrowings | $15 | $6 |
| Accounts payable | 2944 | 2540 |
| Due to related parties | 146 | 189 |
| Contract liabilities | 1896 | 1864 |
| All other current liabilities | 2190 | 2162 |
| **Current liabilities** | **7191** | **6761** |
| Long-term borrowings | 8234 | 31 |
| Compensation and benefits | 549 | 751 |
| Deferred income taxes | 370 | 385 |
| All other liabilities | 1603 | 1484 |
| **Total liabilities** | **17947** | **9412** |
| Commitments and contingencies |  |  |
| **Redeemable noncontrolling interests** | **230** | **220** |
| Common stock, par value $0.01 per share, 100,000 shares authorized, 100 shares issued and outstanding as of 2022; none issued and outstanding as of 2021 |  |  |
| Net parent investment | 11235 | 17692 |
| Accumulated other comprehensive income (loss) – net | (1878) | (1037) |
| **Total equity attributable to GE HealthCare** | **9357** | **16655** |
| Noncontrolling interests | 5 | 21 |
| **Total equity** | **9362** | **16676** |
| **Total liabilities, redeemable noncontrolling interests, and equity** | $**27539** | $**26308** |

---

\* Non-GAAP financial measure.

------

---

| | | |
|:---|:---|:---|
| | **Years ended December 31** | **Years ended December 31** |
| **Unaudited Combined Statements of Cash Flows**<br>***(In millions)*** | **2022** | **2021** |
| Net income | $1967 | $2293 |
| Income from discontinued operations, net of taxes | 18 | 18 |
| Net income from continuing operations | $**1949** | $**2275** |
| Adjustments to reconcile Net income from continuing operations to Cash from (used for) operating activities |  |  |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization of property, plant, and equipment | 228 | 225 |
| &nbsp;&nbsp;&nbsp;Amortization of intangible assets | 405 | 400 |
| &nbsp;&nbsp;&nbsp;Gain on fair value remeasurement of contingent consideration | (65) |  |
| &nbsp;&nbsp;&nbsp;Provision for income taxes | 563 | 600 |
| &nbsp;&nbsp;&nbsp;Cash paid during the year for income taxes | (851) | (615) |
| &nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities, excluding the effects of acquisitions and dispositions: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Receivables | (231) | (1336) |
| &nbsp;&nbsp;&nbsp;&nbsp;Due from related parties | 13 | 157 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories | (402) | (435) |
| &nbsp;&nbsp;&nbsp;&nbsp;Contract and other deferred assets | (222) | 23 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 481 | 263 |
| &nbsp;&nbsp;&nbsp;&nbsp;Due to related parties | (33) | (21) |
| &nbsp;&nbsp;&nbsp;&nbsp;Contract liabilities | 138 | (21) |
| All other operating activities | 161 | 92 |
| **Cash from (used for) operating activities – continuing operations** | **2134** | **1607** |
| **Cash flows – investing activities** |  |  |
| Additions to property, plant, and equipment | (310) | (242) |
| Dispositions of property, plant, and equipment | 4 | 15 |
| Additions to internal-use software |  | (6) |
| Purchases of businesses, net of cash acquired |  | (1481) |
| All other investing activities | (92) | (47) |
| **Cash from (used for) investing activities – continuing operations** | **(398)** | **(1761)** |
| **Cash flows – financing activities** |  |  |
| Net increase (decrease) in borrowings (maturities of 90 days or less) | 9 | (7) |
| Newly issued debt, net of debt issuance costs (maturities longer than 90 days) | 8198 | 5 |
| Repayments and other reductions (maturities longer than 90 days) | (3) | (10) |
| Transfers (to) from Parent | (8934) | (238) |
| All other financing activities | (92) | (13) |
| **Cash from (used for) financing activities – continuing operations** | **(822)** | **(263)** |
| Cash from (used for) operating activities – discontinued operations | (21) |  |
| Cash from (used for) investing activities – discontinued operations |  |  |
| Cash from (used for) financing activities – discontinued operations |  |  |
| Effect of foreign currency rate changes on cash, cash equivalents, and restricted cash | (3) | (34) |
| **Increase (decrease) in cash, cash equivalents, and restricted cash** | **890** | **(451)** |
| Cash, cash equivalents, and restricted cash at beginning of year | 561 | 1012 |
| Less cash, cash equivalents, and restricted cash of discontinued operations at December 31 |  |  |
| Cash, cash equivalents, and restricted cash as of December 31 | $1451 | $561 |
| **Supplemental disclosure of cash flows information** |  |  |
| Cash paid during the year for interest | $— | $(21) |
| **Non-cash investing and financing activities** |  |  |
| Purchase of property, plant, and equipment included in accounts payable | $43 | $29 |

---

\* Non-GAAP financial measure.

------

**Non-GAAP Financial Measures**

The non-GAAP financial measures presented in this press release are supplemental measures of GE HealthCare's performance and its liquidity that the Company believes will help investors understand its financial condition, cash flows and operating results and assess its future prospects. The Company believes that presenting these non-GAAP financial measures, in addition to the corresponding U.S. GAAP financial measures, are important supplemental measures that exclude non-cash or other items that may not be indicative of or are unrelated to its core operating results and the overall health of the Company. These non-GAAP financial measures provide investors greater transparency to the information used by management for its operational decision-making and allows investors to see results "through the eyes of management." The Company believes that providing this information assists investors in understanding its operating performance and the methodology used by management to evaluate and measure such performance. When read in conjunction with the Company's U.S. GAAP results, these non-GAAP financial measures provide a baseline for analyzing trends in the Company's underlying businesses and can be used by management as one basis for financial, operational, and planning decisions. Finally, these measures are often used by analysts and other interested parties to evaluate companies within the Company's industry.

The Company defines these non-GAAP financial measures as:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Organic revenue: Total revenues excluding the effects of: (1) net sales from recent acquisitions and divestitures with less than a full year of comparable net sales; and (2) foreign currency exchange rate fluctuations in order to present revenue on a constant currency basis.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Organic revenue growth rate: Rate of change when comparing Organic revenue, period over period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBIT: Net income attributable to GE HealthCare excluding the effects of: (1) Interest and other financial charges – net; (2) Non-operating benefit (income) costs; (3) Provision (benefit) for income taxes; (4) Income (loss) from discontinued operations, net of taxes; (5) Net (income) loss attributable to noncontrolling interests; (6) restructuring costs; (7) acquisition, disposition related charges (benefits); (8) Spin-Off and separation costs; (9) (gain)/loss of business dispositions/divestments; (10) amortization of acquisition related intangible assets; and (11) investment revaluation (gain)/loss. In addition, the Company may from time to time consider excluding other nonrecurring items to enhance comparability between periods.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBIT margin: Adjusted EBIT divided by Total revenues for the same period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Standalone Adjusted EBIT: Adjusted EBIT including the effects of recurring and on-going costs to operate new functions required for a standalone company that management believes provide a better depiction of the operations of GE HealthCare as a standalone company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Standalone Adjusted EBIT margin: Standalone Adjusted EBIT divided by Total revenues for the same period.

The Company believes Adjusted EBIT, Adjusted EBIT margin, Standalone Adjusted EBIT, and Standalone Adjusted EBIT margin provide management and investors with additional understanding of its business by highlighting the results from ongoing operations and the underlying profitability factors. These metrics exclude interest expense, interest income, and tax expense, as well as unique and/or non-cash items, that can have a material impact on the Company's results. The Company believes this provides additional insight into how its businesses are performing, on a normalized basis. However, these non-GAAP financial measures should not be construed as inferring that the Company's future results will be unaffected by the items for which the measure adjusts.

\* Non-GAAP financial measure.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted Net Income: Net income attributable to GE HealthCare excluding (1) Non-operating benefit (income) costs; (2) restructuring costs; (3) acquisition, disposition related charges (benefits); (4) Spin-Off and separation costs; (5) (gain)/loss of business dispositions/divestments; (6) amortization of acquisition-related intangible assets; (7) investment revaluation (gain)/loss; (8) tax effect of reconciling items (items 1-7); (9) certain tax adjustments as described in Adjusted tax expense definition below and (10) Income (loss) from discontinued operations, net of taxes. In addition, the Company may from time to time consider disclosing other nonrecurring items to enhance comparability between periods.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EPS: Earnings per share from continuing operations excluding the per share impact of: 1) Non-operating benefit (income) costs; (2) restructuring costs; (3) acquisition, disposition related charges (benefits); (4) Spin-Off and separation costs; (5) (gain)/loss of business dispositions/divestments; (6) amortization of acquisition-related intangible assets; (7) investment revaluation (gain)/loss; (8) tax effect of reconciling items (items 1-7); and (9) certain tax adjustments as described in Adjusted tax expense definition below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Standalone Adjusted EPS: Adjusted EPS including the per share impact of the effects of recurring and on-going costs to operate new functions required for a standalone company and interest expense associated with third party debt that management believes provide a better depiction of the operations of GE HealthCare as a standalone company.

The Company believes Adjusted net income, Adjusted EPS, and Standalone Adjusted EPS provide investors with improved comparability of underlying operating results and a further understanding and additional transparency regarding how it evaluates the business. These non-GAAP financial measures also provide management and investors with additional perspective regarding the impact of certain significant items on the Company's combined earnings. However, they should not be construed as inferring that the Company's future results will be unaffected by the items for which the measure adjusts.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted tax expense and Adjusted effective tax rate (ETR): Adjusted tax expense is Income tax expense less the income tax related to EBIT adjustments above and certain income tax adjustments. Examples of income tax adjustments include the impact of tax legislation and the establishment or reversal of significant deferred tax asset valuation allowances. Adjusted ETR is Adjusted tax expense divided by Income before income taxes less EBIT adjustments above. Adjusted tax expense and Adjusted ETR can be used by investors to review the income tax expense and effective tax rate for the Company's operations on a consistent basis.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Free cash flow: Cash from (used for) operating activities - continuing operations adjusting for the effects of (1) additions to PP&E and internal-use software; (2) dispositions of PP&E; and (3) impact of factoring programs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Free cash flow conversion: Free cash flow divided by Adjusted net income.

The Company believes that Free cash flow and Free cash flow conversion provide management and investors with important measures of the Company's ability to generate cash on a normalized basis. These metrics also provide insight into the Company's flexibility to allocate capital, including reinvesting in the company for future growth, paying down debt, paying dividends, and pursuing other opportunities that may enhance stockholder value. The Company believes investors may find it useful to compare Free cash flow performance without the effects of the factoring program discontinuation. The cash flow from operating activity impact from factoring programs discontinued in 2021 represents the cash that the Company would have otherwise collected in the period had customer receivables not been previously sold to General Electric Company ("GE") in those discontinued programs.

\* Non-GAAP financial measure.

------

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended December 31** | **Three months ended December 31** | **Three months ended December 31** | **Years ended December 31** | **Years ended December 31** | **Years ended December 31** |
| **Unaudited Organic Revenue\***<br>***($ In millions)*** | **2022** | **2021** | **% change** | **2022** | **2021** | **% change** |
| **Imaging revenues** | $**2709** | $**2437** | **11%** | $**9985** | $**9433** | **6%** |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Acquisitions<sup>(a)</sup> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Dispositions<sup>(b)</sup> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Foreign currency exchange | (158) |  |  | (413) |  |  |
| **Imaging organic revenue\*** | $**2867** | $**2437** | **18%** | $**10398** | $**9433** | **10%** |
| **Ultrasound revenues** | $**956** | $**898** | **6%** | $**3422** | $**3172** | **8%** |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Acquisitions<sup>(a)</sup> | 63 |  |  | 237 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Dispositions<sup>(b)</sup> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Foreign currency exchange | (67) |  |  | (182) |  |  |
| **Ultrasound organic revenue\*** | $**960** | $**898** | **7%** | $**3367** | $**3172** | **6%** |
| **PCS revenues** | $**786** | $**735** | **7%** | $**2916** | $**2915** | **—%** |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Acquisitions<sup>(a)</sup> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Dispositions<sup>(b)</sup> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Foreign currency exchange | (25) |  |  | (73) |  |  |
| **PCS organic revenue\*** | $**811** | $**735** | **10%** | $**2989** | $**2915** | **3%** |
| **PDx revenues** | $**473** | $**500** | **(5)%** | $**1958** | $**2018** | **(3)%** |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Acquisitions<sup>(a)</sup> |  |  |  | 2 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Dispositions<sup>(b)</sup> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Foreign currency exchange | (37) |  |  | (100) |  |  |
| **PDx organic revenue\*** | $**510** | $**500** | **2%** | $**2056** | $**2018** | **2%** |
| **Other revenues** | $**14** | $**19** | **(26)%** | $**60** | $**47** | **28%** |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Acquisitions<sup>(a)</sup> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Dispositions<sup>(b)</sup> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Foreign currency exchange | (1) |  |  | (3) |  |  |
| **Other organic revenue\*** | $**15** | $**19** | **(21)%** | $**63** | $**47** | **34%** |
| **Total revenues** | $**4938** | $**4589** | **8%** | $**18341** | $**17585** | **4%** |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Acquisitions<sup>(a)</sup> | 63 |  |  | 239 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Dispositions<sup>(b)</sup> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Foreign currency exchange | (288) |  |  | (771) |  |  |
| **Organic revenue\*** | $**5163** | $**4589** | **13%** | $**18873** | $**17585** | **7%** |

---

(a)Represents revenue attributable to acquisitions from the date the Company completed the transaction through the end of four quarters following the transaction.

(b)Represents revenue attributable to dispositions for the four quarters preceding the disposition date.

\* Non-GAAP financial measure.

------

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended December 31** | **Three months ended December 31** | **Three months ended December 31** | **Years ended December 31** | **Years ended December 31** | **Years ended December 31** |
| **Unaudited Adjusted EBIT\***<br>***($ In millions)*** | **2022** | **2021** | **% change** | **2022** | **2021** | **% change** |
| **Net income attributable to GE HealthCare&nbsp;&nbsp;&nbsp;&nbsp;** | **554** | **564** | **(2)%** | **1916** | **2247** | **(15)%** |
| Add: Interest and other financial charges - net&nbsp;&nbsp;&nbsp;&nbsp; | 59 | 6 |  | 77 | 40 |  |
| Add: Non-operating benefit (income) costs&nbsp;&nbsp;&nbsp;&nbsp; | (1) | 1 |  | (5) | 3 |  |
| Less: Benefit (provision) for income taxes | (151) | (179) |  | (563) | (600) |  |
| Less: Income (loss) from discontinued operations, net of taxes | 6 |  |  | 18 | 18 |  |
| Less: Net (income) loss attributable to noncontrolling interests &nbsp;&nbsp;&nbsp;&nbsp; | (19) | (12) |  | (51) | (46) |  |
| **EBIT\*&nbsp;&nbsp;&nbsp;&nbsp;** | **776** | **762** | **2%** | **2584** | **2918** | **(11)%** |
| Add: Restructuring costs<sup>(a)&nbsp;&nbsp;&nbsp;&nbsp;</sup> | 36 | 28 |  | 146 | 155 |  |
| Add: Acquisition, disposition related charges (benefits)<sup>(b)&nbsp;&nbsp;&nbsp;&nbsp;</sup> | (14) | 11 |  | (34) | 14 |  |
| Add: Spin-Off and separation costs<sup>(c)&nbsp;&nbsp;&nbsp;&nbsp;</sup> | 7 |  |  | 14 |  |  |
| Add: (Gain)/loss of business dispositions /divestments<sup>(d)&nbsp;&nbsp;&nbsp;&nbsp;</sup> |  | 2 |  | (1) | (2) |  |
| Add: Amortization of acquisition-related intangible assets&nbsp;&nbsp;&nbsp;&nbsp; | 31 | 23 |  | 121 | 90 |  |
| Add: Investment revaluation (gain)/loss<sup>(e)</sup>&nbsp;&nbsp;&nbsp;&nbsp; | 8 | 1 |  | 31 | (3) |  |
| **Adjusted EBIT\*&nbsp;&nbsp;&nbsp;&nbsp;** | **844** | **827** | **2%** | **2861** | **3172** | **(10)%** |
| **Net income margin** | **11.2%** | **12.3%** | **(110) bps** | **10.4%** | **12.8%** | **(240) bps** |
| **Adjusted EBIT margin\*&nbsp;&nbsp;&nbsp;&nbsp;** | **17.1%** | **18.0%** | **(90) bps** | **15.6%** | **18.0%** | **(240) bps** |

---

(a)Consists of severance, facility closures, and other charges associated with historical restructuring programs.

(b)Consists of legal, consulting, and other transaction and integration fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions.

(c)Costs incurred in the Spin-Off and separation from GE including system implementation, audit and advisory fees, legal entity separation, and other one-time costs.

(d)Consists of gains and losses resulting from the sale of assets and investments.

(e)Primarily relates to valuation adjustments for equity investments.

\* Non-GAAP financial measure.

------

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended December 31** | **Three months ended December 31** | **Three months ended December 31** | **Years ended December 31** | **Years ended December 31** | **Years ended December 31** |
| **Unaudited Adjusted Net Income\***<br>***($ In millions)*** | **2022** | **2021** | **% change** | **2022** | **2021** | **% change** |
| **Net income attributable to GE HealthCare** | $**554** | $**564** | **(2)%** | $**1916** | $**2247** | **(15)%** |
| &nbsp;&nbsp;&nbsp;&nbsp;Add: Non-operating benefit (income) costs | (1) | 1 |  | (5) | 3 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Add: Restructuring costs<sup>(a)</sup> | 36 | 28 |  | 146 | 155 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Add: Acquisition, disposition related charges<sup>(b)</sup> | (14) | 11 |  | (34) | 14 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Add: Spin off and separation costs<sup>(c)</sup> | 7 |  |  | 14 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Add: Gain/loss of business dispositions/divestments<sup>(d)</sup> |  | 2 |  | (1) | (2) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Add: Amortization of acquisition related intangible assets | 31 | 23 |  | 121 | 90 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Add: Investment revaluation (gain)/loss<sup>(e)</sup> | 8 | 1 |  | 31 | (3) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Add: tax effect of reconciling items | (19) | (13) |  | (67) | (62) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Certain tax adjustments<sup>(f)</sup> |  |  |  |  | 77 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Income (loss) from discontinued operations, net of taxes | 6 |  |  | 18 | 18 |  |
| **Adjusted net income\*** | $**596** | $**617** | **(3)%** | $**2103** | $**2347** | **(10)%** |

---

(a)Consists of severance, facility closures, and other charges associated with historical restructuring programs.

(b)Consists of legal, consulting, and other transaction and integration fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions.

(c)Costs incurred in the Spin-Off and separation from GE including system implementation, audit and advisory fees, legal entity separation, and other one-time costs.

(d)Consists of gains and losses resulting from the sale of assets and investments.

(e)Primarily relates to valuation adjustments for equity investments.

(f)Consists of certain income tax adjustments, such as the impact of tax legislation and the establishment or reversal of significant deferred tax asset valuation allowances.

\* Non-GAAP financial measure.

------

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended December 31** | **Three months ended December 31** | **Three months ended December 31** | **Years ended December 31** | **Years ended December 31** | **Years ended December 31** |
| **Unaudited Free Cash Flow\***<br>***($ In millions)*** | **2022** | **2021** | **% change** | **2022** | **2021** | **% change** |
| **Cash from (used for) operating activities – continuing operations&nbsp;&nbsp;&nbsp;&nbsp;** | $**1063** | $**(11)** | **F** | $**2134** | $**1607** | **33%** |
| **Cash flow conversion** |  |  |  | **111%** | **72%** | **39 pts** |
| &nbsp;&nbsp;&nbsp;&nbsp;Add: Additions to PP&E and internal-use software | (77) | (73) |  | (310) | (248) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Add: Dispositions of PP&E | 1 | (1) |  | 4 | 15 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Add: Impact of discontinued factoring programs<sup>(a)</sup>&nbsp;&nbsp;&nbsp;&nbsp; |  | 636 |  |  | 1453 |  |
| **Free cash flow\*&nbsp;&nbsp;&nbsp;&nbsp;** | $**987** | $**551** | **79%** | $**1828** | $**2827** | **(35)%** |
| **Free cash flow conversion\*** |  |  |  | **87%** | **120%** | **(33) pts** |

---

(a) Adjustment to present net cash flows from operating activities from continuing operations had the Company not factored receivables with GE's Working Capital Solutions ("WCS"). By the end of 2021, factoring of receivables with WCS was discontinued.

**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended December 31** | **Three months ended December 31** | **Three months ended December 31** | **Year ended December 31** | **Year ended December 31** | **Year ended December 31** |
| **Unaudited Adjusted Earnings Per Share\***<br>***(In dollars)*** | **2022** | **2021** | **$ change** | **2022** | **2021** | **$ change** |
| **Basic and diluted earnings per share - Continuing operations** | $**1.21** | $**1.24** | $**(0.04)** | $**4.18** | $**4.91** | $**(0.73)** |
| &nbsp;&nbsp;&nbsp;Add: Non-operating benefit (income) costs&nbsp;&nbsp;&nbsp;&nbsp; | (0.00) | 0.00 |  | (0.01) | 0.01 |  |
| &nbsp;&nbsp;&nbsp;Add: Restructuring costs<sup>(a)&nbsp;&nbsp;&nbsp;&nbsp;</sup> | 0.08 | 0.06 |  | 0.32 | 0.34 |  |
| &nbsp;&nbsp;&nbsp;Add: Acquisition and disposition related charges (benefits)<sup>(b)</sup>&nbsp;&nbsp;&nbsp;&nbsp; | (0.03) | 0.02 |  | (0.07) | 0.03 |  |
| &nbsp;&nbsp;&nbsp;Add: Spin-Off and separation costs<sup>(c)</sup>&nbsp;&nbsp;&nbsp;&nbsp; | 0.02 |  |  | 0.03 |  |  |
| &nbsp;&nbsp;&nbsp;Add: (Gain)/loss of business dispositions/divestments<sup>(d)</sup>&nbsp;&nbsp;&nbsp;&nbsp; |  | 0.00 |  | (0.00) | (0.00) |  |
| &nbsp;&nbsp;&nbsp;Add: Amortization of acquisition-related intangible assets&nbsp;&nbsp;&nbsp;&nbsp; | 0.07 | 0.05 |  | 0.27 | 0.20 |  |
| &nbsp;&nbsp;&nbsp;Add: Investment revaluation (gain)/loss<sup>(e)</sup>&nbsp;&nbsp;&nbsp;&nbsp; | 0.02 | 0.00 |  | 0.07 | (0.01) |  |
| &nbsp;&nbsp;&nbsp;Add: Tax effect of reconciling items | (0.04) | (0.03) |  | (0.15) | (0.14) |  |
| &nbsp;&nbsp;&nbsp;Less: Certain tax adjustments<sup>(f)</sup>&nbsp;&nbsp;&nbsp;&nbsp; |  |  |  |  | 0.17 |  |
| **Adjusted basic and diluted earnings per share\***<sup>(g)</sup>**&nbsp;&nbsp;&nbsp;&nbsp;** | $**1.31** | $**1.36** | $**(0.05)** | $**4.63** | $**5.17** | $**(0.54)** |

---

(a) Consists of severance, facility closures, and other charges associated with historical restructuring programs.

(b) Consists of legal, consulting, and other transaction and integration fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions.

(c) Costs incurred in the Spin-Off and separation from GE, including system implementation, audit and advisory fees, legal entity separation, and other one-time costs.

(d) Consists of gains and losses resulting from the sale of assets and investments.

(e) Primarily relates to valuation adjustments for equity investments.

(f) Consists of certain income tax adjustments, such as the impact of tax legislation and the establishment or reversal of significant deferred tax asset valuation allowances.

(g) Adjusted earnings-per-share amounts are computed independently, thus, the sum of per-share amounts may not equal the total.

\* Non-GAAP financial measure.

------

---

| | | |
|:---|:---|:---|
| **Unaudited Net Income to Estimated Standalone Adjusted EBIT\*** | **Unaudited Net Income to Estimated Standalone Adjusted EBIT\*** | **Unaudited Net Income to Estimated Standalone Adjusted EBIT\*** |
| | **Three months ended December 31** | **Year ended December 31** |
| ***($ In millions)*** | **2022** | **2022** |
| **Net income attributable to GE HealthCare** | $**554** | $**1916** |
| &nbsp;&nbsp;&nbsp;Add: Interest and other financial charges - net | 59 | 77 |
| &nbsp;&nbsp;&nbsp;Add: Non-operating benefit (income) costs | (1) | (5) |
| &nbsp;&nbsp;&nbsp;Less: Benefit (provision) for income taxes | (151) | (563) |
| &nbsp;&nbsp;&nbsp;Less: Income from discontinued operations, net of taxes | 6 | 18 |
| &nbsp;&nbsp;&nbsp;Less: Net (income) loss attributable to noncontrolling interests | (19) | (51) |
| **EBIT\*** | $**776** | $**2584** |
| &nbsp;&nbsp;&nbsp;Add: Restructuring costs<sup>(a)</sup> | 36 | 146 |
| &nbsp;&nbsp;&nbsp;Add: Acquisition and disposition related charges (benefits)<sup>(b)</sup> | (14) | (34) |
| &nbsp;&nbsp;&nbsp;Add: Spin-Off and separation costs<sup>(c)</sup> | 7 | 14 |
| &nbsp;&nbsp;&nbsp;Add: (Gain)/loss of business dispositions/divestments<sup>(d)</sup> |  | (1) |
| &nbsp;&nbsp;&nbsp;Add: Amortization of acquisition-related intangible assets | 31 | 121 |
| &nbsp;&nbsp;&nbsp;Add: Investment revaluation (gain)/loss<sup>(e)</sup> | 8 | 31 |
| **Adjusted EBIT\*** | $**844** | $**2861** |
| &nbsp;&nbsp;&nbsp;Less: Estimated standalone costs<sup>(f)</sup> | 50 | 200 |
| &nbsp;&nbsp;&nbsp;Less: Estimated incremental interest expense<sup>(g)</sup> |  |  |
| &nbsp;&nbsp;&nbsp;Less: Estimated tax effect of reconciling items<sup>(h)</sup> |  |  |
| **Standalone Adjusted EBIT\*** | $**794** | $**2661** |
| **Net income margin** | **11.2%** | **10.4%** |
| **Adjusted EBIT margin\*** | **17.1%** | **15.6%** |
| **Standalone adjusted EBIT margin\*** | **16.1%** | **14.5%** |

---

(a) Consists of severance, facility closures, and other charges associated with historical restructuring programs.

(b) Consists of legal, consulting, and other transaction and integration fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions.

(c) Costs incurred in the Spin-Off and separation from GE, including system implementation, audit and advisory fees, legal entity separation, and other one-time costs.

(d) Consists of gains and losses resulting from the sale of assets and investments.

(e) Primarily relates to valuation adjustments for equity investments.

(f) Estimated expense of recurring and ongoing costs required to operate new functions required for a public company such as external reporting, internal audit, treasury, investor relations, board of directors and officers, stock administration, and expanding the services of existing functions such as information technology, finance, supply chain, human resources, legal, tax, facilities, branding, security, government relations, community outreach, and insurance.

(g) Estimated additional interest expense related to the GEHC debt issuances on November 22nd, 2022 and the draw down of the term loan on January 3rd, 2023, the amortization of original issue discount and deferred, debt issuance costs, and certain Euro to U.S. Dollar cross currency interest rate swap arrangements with a notional amount of $2.0 billion. Interest expense was calculated assuming constant debt levels throughout the periods.

(h) Estimated tax effect was determined by applying the respective statutory tax rates to the pre-tax adjustments in jurisdictions where valuation allowances were depending on many factors including, but not limited to, the profitability in local jurisdictions and the legal entity structure implemented post Spin-Off and may be materially different from the estimate.

\* Non-GAAP financial measure.

------

---

| | | |
|:---|:---|:---|
| **Unaudited Net Income to Estimated Standalone Adjusted Net Income\*** | **Unaudited Net Income to Estimated Standalone Adjusted Net Income\*** | **Unaudited Net Income to Estimated Standalone Adjusted Net Income\*** |
| | **Three months ended December 31** | **Year ended December 31** |
| ***($ In millions)*** | **2022** | **2022** |
| **Net income attributable to GE HealthCare** | $**554** | $**1916** |
| &nbsp;&nbsp;&nbsp;Add: Non-operating benefit (income) costs | (1) | (5) |
| &nbsp;&nbsp;&nbsp;Add: Restructuring costs<sup>(a)</sup> | 36 | 146 |
| &nbsp;&nbsp;&nbsp;Add: Acquisition and disposition related charges (benefits)<sup>(b)</sup> | (14) | (34) |
| &nbsp;&nbsp;&nbsp;Add: Spin-Off and separation costs<sup>(c)</sup> | 7 | 14 |
| &nbsp;&nbsp;&nbsp;Add: (Gain)/loss of business dispositions/divestments<sup>(d)</sup> |  | (1) |
| &nbsp;&nbsp;&nbsp;Add: Amortization of acquisition-related intangible assets | 31 | 121 |
| &nbsp;&nbsp;&nbsp;Add: Investment revaluation (gain)/loss<sup>(e)</sup> | 8 | 31 |
| &nbsp;&nbsp;&nbsp;Add: Tax effect of reconciling items | (19) | (67) |
| &nbsp;&nbsp;&nbsp;Less: Income (loss) from discontinued operations, net of taxes | 6 | 18 |
| **Adjusted net income\*** | $**596** | $**2103** |
| &nbsp;&nbsp;&nbsp;Less: Estimated standalone costs<sup>(f)</sup> | 50 | 200 |
| &nbsp;&nbsp;&nbsp;Less: Estimated incremental interest expense<sup>(g)</sup> | 100 | 541 |
| &nbsp;&nbsp;&nbsp;Less: Estimated tax effect of reconciling items<sup>(h)</sup> | (35) | (171) |
| **Standalone Adjusted net income\*** | $**481** | $**1533** |

---

(a) Consists of severance, facility closures, and other charges associated with historical restructuring programs.

(b) Consists of legal, consulting, and other transaction and integration fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions.

(c) Costs incurred in the Spin-Off and separation from GE, including system implementation, audit and advisory fees, legal entity separation, and other one-time costs.

(d) Consists of gains and losses resulting from the sale of assets and investments.

(e) Primarily relates to valuation adjustments for equity investments.

(f) Estimated expense of recurring and ongoing costs required to operate new functions required for a public company such as external reporting, internal audit, treasury, investor relations, board of directors and officers, stock administration, and expanding the services of existing functions such as information technology, finance, supply chain, human resources, legal, tax, facilities, branding, security, government relations, community outreach, and insurance.

(g) Estimated additional interest expense related to the GEHC debt issuances on November 22nd, 2022 and the draw down of the term loan on January 3rd, 2023, the amortization of original issue discount and deferred, debt issuance costs, and certain Euro to U.S. Dollar cross currency interest rate swap arrangements with a notional amount of $2.0 billion. Interest expense was calculated assuming constant debt levels throughout the periods.

(h) Estimated tax effect was determined by applying the respective statutory tax rates to the pre-tax adjustments in jurisdictions where valuation allowances were depending on many factors including, but not limited to, the profitability in local jurisdictions and the legal entity structure implemented post Spin-Off and may be materially different from the estimate.

\* Non-GAAP financial measure.

------

---

| | | |
|:---|:---|:---|
| **Unaudited Continuing Earnings Per Share to Estimated Standalone Adjusted Earnings Per Share\*** | **Unaudited Continuing Earnings Per Share to Estimated Standalone Adjusted Earnings Per Share\*** | **Unaudited Continuing Earnings Per Share to Estimated Standalone Adjusted Earnings Per Share\*** |
| | **Three months ended December 31** | **Year ended December 31** |
| ***(In dollars)*** | **2022** | **2022** |
| **Basic and diluted earnings per share - Continuing operations** | $**1.21** | $**4.18** |
| &nbsp;&nbsp;&nbsp;Add: Non-operating benefit (income) costs | (0.00) | (0.01) |
| &nbsp;&nbsp;&nbsp;Add: Restructuring costs<sup>(a)</sup> | 0.08 | 0.32 |
| &nbsp;&nbsp;&nbsp;Add: Acquisition and disposition related charges (benefits)<sup>(b)</sup> | (0.03) | (0.07) |
| &nbsp;&nbsp;&nbsp;Add: Spin-Off and separation costs<sup>(c)</sup> | 0.02 | 0.03 |
| &nbsp;&nbsp;&nbsp;Add: (Gain)/loss of business dispositions/divestments<sup>(d)</sup> |  | (0.00) |
| &nbsp;&nbsp;&nbsp;Add: Amortization of acquisition-related intangible assets | 0.07 | 0.27 |
| &nbsp;&nbsp;&nbsp;Add: Investment revaluation (gain)/loss<sup>(e)</sup> | 0.02 | 0.07 |
| &nbsp;&nbsp;&nbsp;Add: Tax effect of reconciling items | (0.04) | (0.15) |
| **Adjusted basic and diluted earnings per share\*** | $**1.31** | $**4.63** |
| &nbsp;&nbsp;&nbsp;Less: Estimated standalone costs<sup>(f)</sup> | 0.11 | 0.44 |
| &nbsp;&nbsp;&nbsp;Less: Estimated incremental interest expense<sup>(g)</sup> | 0.22 | 1.19 |
| &nbsp;&nbsp;&nbsp;Less: Estimated tax effect of reconciling items<sup>(h)</sup> | (0.08) | (0.38) |
| **Standalone Adjusted earnings per share\***<sup>(i)</sup> | $**1.06** | $**3.38** |

---

(a) Consists of severance, facility closures, and other charges associated with historical restructuring programs.

(b) Consists of legal, consulting, and other transaction and integration fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions.

(c) Costs incurred in the Spin-Off and separation from GE, including system implementation, audit and advisory fees, legal entity separation, and other one-time costs.

(d) Consists of gains and losses resulting from the sale of assets and investments.

(e) Primarily relates to valuation adjustments for equity investments.

(f) Estimated expense of recurring and ongoing costs required to operate new functions required for a public company such as external reporting, internal audit, treasury, investor relations, board of directors and officers, stock administration, and expanding the services of existing functions such as information technology, finance, supply chain, human resources, legal, tax, facilities, branding, security, government relations, community outreach, and insurance.

(g) Estimated additional interest expense related to the GEHC debt issuances on November 22nd, 2022 and the draw down of the term loan on January 3rd, 2023, the amortization of original issue discount and deferred, debt issuance costs, and certain Euro to U.S. Dollar cross currency interest rate swap arrangements with a notional amount of $2.0 billion. Interest expense was calculated assuming constant debt levels throughout the periods.

(h) Estimated tax effect was determined by applying the respective statutory tax rates to the pre-tax adjustments in jurisdictions where valuation allowances were depending on many factors including, but not limited to, the profitability in local jurisdictions and the legal entity structure implemented post Spin-Off and may be materially different from the estimate.

(i) Adjusted earnings-per-share amounts are computed independently, thus, the sum of per-share amounts may not equal the total

\* Non-GAAP financial measure.

------

**Non-GAAP Financial Measures in Outlook**

GE HealthCare calculates forward-looking non-GAAP financial measures, including Organic revenue growth, Adjusted EBIT margin, Adjusted ETR, Adjusted EPS, and Free cash flow conversion based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. GE HealthCare does not provide reconciliations of these forward-looking non-GAAP financial measures to the respective GAAP metrics as it is unable to predict with reasonable certainty and without unreasonable effort items such as the impact of changes in currency exchange rates, impacts associated with business acquisitions or dispositions, timing and magnitude of restructuring activities and revaluation of strategic investments, amongst other items. The timing and amounts of these items are uncertain and could have a substantial impact on GE HealthCare's results in accordance with GAAP.

**Conference Call and Webcast Information** 

GE HealthCare will discuss its results during its investor conference call today, January 30, 2023 at 8:00am ET. The conference call will be broadcast live via webcast, and the webcast and accompanying slide presentation containing financial information can be accessed by visiting the investor section of the website at https://investor.gehealthcare.com/news-events/events. An archived version of the webcast will be available on the website after the call.

**Forward-looking Statements**

This release contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as "will," "expect," "may," "would," "could," "plan," "believe," "anticipate," "intend," "estimate," "potential," "position," "forecast," "target," "guidance," "outlook," and similar expressions. These forward-looking statements may include, but are not limited to, statements about the Company's expected financial performance, including revenue, profit, taxes, earnings per share, and cash flows, and the Company's outlook; operational improvements; and the Company's strategy, innovation, and investments. These forward-looking statements involve risks and uncertainties, many of which are beyond the Company's control. Factors that could cause the Company's actual results to differ materially from those described in its forward-looking statements include, but are not limited to, operating in highly competitive markets; the actions or inactions of third parties with whom the Company partners and the various collaboration, licensing, and other partnerships and alliances the Company has with third parties; demand for the Company's products, services, or solutions and factors that affect that demand; management of the Company's supply chain and the Company's ability to cost-effectively secure the materials it needs to operate its business; disruptions in the Company's operations; the global COVID-19 pandemic and its effects on the Company's business; maintenance and protection of the Company's intellectual property rights; the impact of potential information technology, cybersecurity or data security breaches; compliance with the various legal, regulatory, tax, and other laws to which the Company is subject and related changes, claims, or actions; environmental, social, and governance matters; the Company's ability to successfully complete strategic transactions; the Company's ability to operate effectively as an independent, publicly-traded company and achieve the benefits the Company expects from its spin-off from General Electric Company; and the incurrence of substantial indebtedness in connection with the spin-off and any related effect on the Company's business. Please also see the "Risk Factors" section of the Company's Form 10 filed with the U.S. Securities and Exchange Commission and any updates or amendments it makes in future filings. There may be other factors not presently known to the Company or

\* Non-GAAP financial measure.

------

which it currently considers to be immaterial that could cause the Company's actual results to differ materially from those projected in any forward-looking statements the Company makes. The Company does not undertake any obligation to update or revise its forward-looking statements except as required by applicable law or regulation.

**About GE HealthCare Technologies Inc.**

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient's journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $18.3 billion business with 50,000 employees working to create a world where healthcare has no limits.

*Follow us on <u>Facebook</u>, <u>LinkedIn</u>, <u>Twitter</u>, <u>Instagram</u> and <u>Insights</u> for the latest news, or visit our website <u>gehealthcare.com</u> for more information.*

**Investor Relations Contact:**

Carolynne Borders

+1-631-662-4317

<u>carolynne.borders@gehealthcare.com</u>

**Media Contact:**

Tor Constantino

+1-585-441-1658

<u>tor.constantino@gehealthcare.com</u>

<br>